McKesson Corporation vs Occidental Petroleum Corporation — how do they compare? McKesson Corporation trades at $921.5 (market cap $106.14B), while Occidental Petroleum Corporation trades at $60.07 (market cap $58.19B). The key difference: McKesson Corporation is the larger of the two by market cap, and Occidental Petroleum Corporation pays the higher dividend (1.92%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Occidental Petroleum Corporation for 92 Days on average.
| MCK | OXY | |
|---|---|---|
Market Cap | $106.14B | $58.19B |
Volume | 794,405 | 7,092,290 |
Sector | Health | Energy |
52-Week High | $995.69 | $66.24 |
52-Week Low | $725.17 | $38.92 |
Typical Hold Time | 74 Days | 92 Days |
Enterprise Value | $112.67B | $76.95B |
Dividend Yield | 0.41% | 1.92% |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Occidental Petroleum (OXY) trades at $60.28, up 3.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by a consensus price target of $71.40, indicating potential upside. Recent news highlights Goldman Sachs' upgrade to Buy, citing cash flow targets and debt reduction. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, but net income margin remains healthy at 30.32%, and the company maintains a solid balance sheet with manageable debt levels.
OXY presents a favorable risk-reward profile with analyst optimism and operational efficiency, though exposure to oil price volatility and competitive pressures pose risks. The upcoming Q3 2026 earnings report on November 9 is a key catalyst. Institutional sentiment is positive, with 52% of analysts rating it Buy. Investors should weigh the stock's valuation appeal against macroeconomic headwinds affecting the energy sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →